|Articles|October 1, 2002
- Applied Clinical Trials-10-01-2002
Bert Spilker
Bert Spilker has been involved in clinical trials for 30 years. He?s written books, founded companies, and helped steer regulatory agencies. Now he wants to change how drugs are developed.
Advertisement
Articles in this issue
almost 24 years ago
IRBs in the Spotlightalmost 24 years ago
Building a Home Networkalmost 24 years ago
A Dream Unfulfilled: European Clinical Trials Rules Are Not Workingalmost 24 years ago
Learn Before You Leapalmost 24 years ago
A Faithful Subjectalmost 24 years ago
Using IVRS in Clinical Trial Managementalmost 24 years ago
The Virtual Training Processalmost 24 years ago
Adding Centers to Boost Subject AccrualAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy
2
Bringing the Voice of Clinical Practice and Patients into Drug Development
3
ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion
4
Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial
5